Antibodies to the human prolactin receptor

Details Antibodies to the human prolactin receptor Antibodies to the human prolactin receptor

2006-10-04

2008-09-09

Rawlings, Stephen L. (Department: 1643)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Fused or hybrid cell, per se

C435S332000, C530S350000, C530S387100, C530S387300, C530S391300

Reexamination Certificate

active

07422899

ABSTRACT:
This invention provides antibodies to the prolactin receptor, particularly the human prolactin receptor. Preferred antibodies are capable of blocking prolactin binding to the prolactin receptor, inhibiting signaling through the prolactin receptor, and/or inhibiting proliferation of cancer cells induced by prolactin. Also provided are nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and uses of the antibodies and nucleic acids.

REFERENCES:
patent: 4474893 (1984-10-01), Reading
patent: 4714681 (1987-12-01), Reading
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4925648 (1990-05-01), Hansen et al.
patent: 5229275 (1993-07-01), Goroff
patent: 5567610 (1996-10-01), Borrebaeck et al.
patent: 5573920 (1996-11-01), Randle
patent: 5585089 (1996-12-01), Queen et al.
patent: 5641870 (1997-06-01), Rinderknecht et al.
patent: 5648237 (1997-07-01), Carter
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5731168 (1998-03-01), Carter et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5789199 (1998-08-01), Joly et al.
patent: 5807706 (1998-09-01), Carter et al.
patent: 5821333 (1998-10-01), Carter et al.
patent: 5840523 (1998-11-01), Simmons et al.
patent: 5869046 (1999-02-01), Presta et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 2002/0155537 (2002-10-01), Carter et al.
patent: 2003/0020734 (2003-01-01), Yin et al.
patent: 2004/0023341 (2004-02-01), Xu et al.
patent: 2005/0036942 (2005-02-01), Devaux et al.
patent: WO 91/00360 (1991-01-01), None
patent: WO 92/05793 (1992-04-01), None
patent: WO 92/08802 (1992-05-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 00/44788 (2000-08-01), None
patent: WO 02/096948 (2002-12-01), None
Banerjee et al (Int. J. Can., 55:712-721, 1993).
Hand et al (Can. Res., 43:728-735, 1983).
Ben-Jonathan et al., “Prolactin as an autocrine/paracrine growth factor in human cancer.” Trends Endocrinol. Metal. 13:245-250 (2002).
Bernichtein et al., “Development of Pure Prolactin Receptor Antagonists.” J. of Biol. Chem. 278(38):35988-35999(2003).
Carter et al., “High LevelEscherichia coliExpression and Production of a Bivalent Humanized Antibody Fragment.” Bio/Technology 10:163-167 (1992)
Carter et al., “Humanization of an anit-p185Her2antibody for human cancer therapy.” Proc. Natl. Acad. Sci. USA 89:4285 (1992).
Chen et al., “A Human Prolactin Antagonist, hPRL-G129R, Inhibits Breast Cancer Cell Proliferation through Induction of Apoptosis.” Clin. Cancer Res. 5:3583-3593 (1999).
Chen et al., “In vivo studies of the anti-tumor effects of a human prolactin agtagonist, hPRL-G129R.” Int. J. Oncol. 20:813-818 (2002).
Chothia and Lesk “Canonical Structures for the Hypervariable Regions of Immunoglobulins.” J. Mol. Biol., 196:901-917 (1987).
Clackson et al., “Making antibody fragments using phage display libraries.” Nature, 352:624-628 (1991).
Clevenger et al., “Expression of Prolactin and Prolactin Receptor in Human Breast Carcinoma.” Am. J. of Path. 146(3):695-705 (1995).
Clevenger et al., “The Role of Prolactin in Mammary Carcinoma.” Endocrine Reviews, 24(1):1-27 (2003).
Clevenger et al., “Prolactin receptor signal transduction in cells of the immune system.” J Endocrinol 157, 187-197 (1998).
Evan et al., “Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product.” Molecular and Cellular Biology, 5:3610-3616 (1985).
Field et al., “Purification of a RAS-Responsive Andenylyl Cyplase Complex from Saccharomyces serevisiae by Use of an Epitope Addition Method.” Mol. Cell. Biol., 8:2159-2165 (1988).
Fraker et al., “Protein and Cell Membrane Iodinations With a Sparingly Soluble Chloroamide, 1,3,4,6-Tetrachloro-3a,6a-Diphenylglycoluril.” Biochem. Biophys. Res. Commun. 80:49-57(1978).
Fuh et al., “Prolactin Receptor Antagonists that Inhibit the Growth of Breast Cancer Cell Lines.” J. Biol. Chem. 270(22):13133-13137 (1995).
Gazzano-Santoro et al., “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody.” J. Immunol. Methods 202:163-171 (1996).
Ginsburg et al., “Prolactin synthesis and secretion by human breast cancer cells.” Cance Res. 55:2591-2595 (1995).
Goffin et al., “Prolactin:The New Biology of an Old Hormone.” Annu. Rev. Physiol. 64:47-67 (2002).
Goffin et al., “The Prolactin/Growth Hormone Receptor Family: Structure/Function Relationships.” J. Mammary Gland Biol. And Neoplasia 2(1):7-17 (1997).
Hamers Casterman et al., “Naturally occurring antibodies devoid of light chains.” Nature 363:446 448 (1993).
Hankinson et al., “Plasma Prolactin Levels and Subsequent Risk of Breast Cancer in Postmenopausal Women.” J. Natl. Cancer Inst. 91(7):629-34 (1999).
Haspel et al., “System for Cleavable Fc Fusion Proteins Using Tobacco Etch Virus (TEF) Protease.” Biotechniques 30(1): 60-66 (2001).
Hopp et al., “A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification.” BioTechnology, 6:1204-1210 (1988).
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse.” Nature, 321:522-525 (1986).
Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity.” Nature, 256:495-497 (1975).
Kostelny et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers.” J. Immunol. 148:1547-1553 (1992).
Llovera et al., “Involvement of prolactin in breast cancer: redefining the molecular targets.” Experimental Geronotology, Elsevier, 35:41-51 (2000).
Lutz-Freyermuth et al., “Quantitative determination that one of the two potential RNA-binding domains of the A protein component of the U1 small nuclear ribonucleoprotein complex binds with the high affinity to stem-loop II of U1 RNA.” Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990).
Marks et al., “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling.” Bio/Technology, 10:779-783 (1992).
Marks et al., “By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage.” J. Mol. Biol., 222:581-597 (1991).
Martin et al., “GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrail K+ Channel Currents.” Science, 255:192-194 (1992).
McCafferty et al., “Phage Antibodies: filamentous phase displaying antibody variable domain.” Nature, 348:552-554 (1990).
Millstein et al., “Hybrid hybridomas and their use in immunohistochemistry.” Nature 305:537-539 (1983).
Paborsky et al., “Mammalian cell transient expression of tissue factor for the production of antigen.” Protein Engineering, 3(6):547-553 (1990).
Pellegrini et al., Expression of Prolactin and Its Receptor in Human Lymphoid Cells. Mol Endocrinol 6, 1023-1031 (1992).
Perks et al., “Prolactin acts as a potent survival factor for human breast cancer cell lines.” Br. J. Cancer 91:305-311 (2004).
Presta et al., “Humanization of an Antibody Directed Against IgE.” J. Immunol. 151:2623-2632 (1993).
Reichmann et al., “Reshaping human antibodies for therapy.” Nature, 332:323-327 (1988).
Robbins and Angell, Basic Pathology, 2d Ed., W.B. Saunders Co., Philadelphia, pp. 68-79 (1976).
Roux et al., “Comparisons of the Ability of Human IgG3 Hinge Mutants, IgM, IgE, and IgA2, Form Small Immune Complexes:A role for Flexibility and Geometry.” J. Immunol. 161:4083-4090 (1998).
Sims et al., “A Humanized CD18 Antibody Can Block Function without Cell Destruction.” J. Immunol. 151:2296-2308 (1993).
Skinner et al., “Use of the Glu-Glu-Phe C-terminal Epitope for Rapid Purification

Affiliated with

Also associated with

Rating

Antibodies to the human prolactin receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to the human prolactin receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to the human prolactin receptor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3979258